55 Plus Lecture Series - Towards a World Without Disease

Date:  May 31, 2018
Topic:  Towards a World Without Disease
Speaker:  William Hait, Global Head, Janssen Research & Development, LLC
(This lecture has been rescheduled from January 4, 2018)  

Most drugs are designed to manage chronic disease states such as diabetes, hypertension, congestive heart failure and more recently, cancer.  With the exception of infectious and some forms of cardiovascular diseases, far less is done to prevent, intercept a disease-causing process or curing disease.  At Johnson and Johnson, we have embarked on programs to create "immorbidity", i.e. living a life free of disease. 

William N. Hait, M.D., Ph.D. is Global Head, Janssen Research & Development, LLC, the global research and development arm of Janssen, the pharmaceutical companies of Johnson & Johnson.  In this role, he leads the global Research & Development (R&D) group in its mission to discover and develop innovative new medicines to address the world's most serious unmet medical needs.  Bill joined the Johnson & Johnson Family of Companies in 2007 and assumed the role of Global Therapeutic Area Head, Oncology, in 2009.  Before that he was the founding Director of The (Rutgers) Cancer Institute of New Jersey, which he led to receive the National Cancer Institute's highest designation of Comprehensive Cancer Center in 2002.  From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.  After earning his B.A. from the University of Pennsylvania, Bill received his M.D. and Ph.D. cum laude from the Medical College of Pennsylvania where he was elected to Alpha Omega Alpha.  He joined the faculty of Yale University School of Medicine in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit.  He is Board Certified in Internal Medicine and Medical Oncology.  Bill has received numerous awards and honors including the Burroughs Wellcome Award in Clinical Pharmacology, election to the American Society of Clinical Investigation, and in 2013 he was elected as a Fellow of the AACR Academy.